Synthesis and activity evaluation of 2-(1-naphtho[2,1- b ]furan-2-yl-carbonyl)-3,5-disubstituted-2,3-dihydro-1H-pyrazoles

*Corresponding Author:

vaidya V
Department of PG Studies and Research in Chemistry, School of Chemical Sciences, Kuvempu University, Jnana Sahyadri, Shankaraghatta-577 451, India
E-mail: vaidyavijaya@hotmail.com

Abstract

Ethyl naphtho[2,1- b ]furan-2-carboxylate (2) on reaction with hydrazine hydrate in presence of acid catalyst in ethanol medium affords naphtho[2,1-b]furan-2-carbohydrazide (3). The reaction of substituted acetophenones (4a-c) with aromatic aldehydes (5a-e) produces chalcones (6a-o) via the Claisen condensation. The reaction of naphtho[2,1- b ]furan-2-carbohydrazide (3) with chalcones (6a-6o) in presence of acetic acid as catalyst in dioxane produces 1-(naphtho[2,1- b ]furan-2-yl-carbonyl)-3,5-disubstituted-2,3-dihydro-1H-pyrazoles (7a-o). The structures of newly synthesized compounds have been established by elemental analysis and spectral studies. The compounds 7a-o have been evaluated for their antimicrobial activity and some selected compounds evaluated for antiinflammatory, analgesic, anthelmintic, diuretic and antipyretic activities.

Keywords

Naphtho[2,1-b]furan, naphthofuropyrazoles, pyrazoles, pharmacological activities

The pyrazole-based derivatives have shown several biological activities, many of them are currently being tested and/or clinically evaluated for new drug discovery [1]. Various pyrazole and pyrazoline derivatives have been reported to possess antinociceptive effect in mice [2], antimicrobial [3,4], insecticidal [5] and local anesthetic [6] activities. Some of the pyrazole derivatives also serve as intermediates in dye industry [7] and act as growth inhibitors of phytopathogenic fungi [8]. The biheterocyclic compounds in which pyrazole moiety is coupled with furan or benzofuran nucleus exhibit antimicrobial and antiinß ammatory activities [9-10]. However there are no reports in literature concerning coupling of pyrazole ring with another biologically active naphtho[2,1-b] furan nucleus, either directly or through carbon bridge.

Receiving impetus from these reports, guided by the principle that combination of two or more biologically active heterocyclic systems enhances the biological proÞ le of molecules many folds [11] and in continuation of our research for more potent derivatives of naphtho[2,1-b]furan derivatives12-17, we report in this paper synthesis and pharmacological investigation of novel biheterocyclics, 1-(naphtho[2,1-b]furan-2-ylcarbonyl- 3,5-disubstituted-2,3-dihydro-1H-pyrazoles (7a-7o) bridged via carbonyl group.

Materials and Methods

Melting points were determined with open capillary and are uncorrected. IR spectra were recorded in KBr pellets by using Shimadzu FT-IR 8000 Spectrometer. ¹H NMR and ¹³C NMR were recorded in DMSO-d [6] on Bruker-400 MHz Spectrometer. Chemical shifts are recorded in δ relative to TMS as internal standard. Mass spectral data were obtained on a Brucker Apex-II Mass Spectrometer. Elemental analyses were performed using a Vario-EL elemental analyzer. Purity of the compounds was checked by TLC. All the animals were maintained under standard conditions and had access to pelleted animal feed and water. The study protocols were approved by the institutional animal ethics committee (CPCSEA Regd. No.157/1999).

Chemical synthesis

To a solution of 2-hydroxy-1-naphthaldehyde (1) (5.16 g, 0.03 mol) in dry N,N-dimethylformamide (25 ml), ethylchloroacetate (3.66 g, 0.03 mol) and anhydrous potassium carbonate (12.4 g, 0.9 mol) were added and the reaction mixture was reß uxed on water bath for 24 h. The reaction mixture was then poured into ice cold water, to obtain the product ethyl naphtho-[2,1-b] furan-2-carboxylate (2) as solid, which was collected by Þ ltration, dried and recrystallised from ethanol.

A mixture of ethyl naphtho-[2,1-b]furan-2-carboxylate (2) (2.40 g, 0.01 mol), catalytic amount of concentrated hydrochloric acid and hydrazine hydrate (1 g, 0.02 mol) were refluxed in absolute ethanol (25 ml) for 2 h on water bath. Then the reaction mixture was cooled to room temperature, the solid thus obtained was filtered and dried. The product, naphtho-[2,1-b]furan-2-carbohydrazide (3) obtained was recrystallised from ethanol.

Freshly distilled acetophenone (4) (2.6 g, 0.0215 mol) was added to a cooled mixture of sodium hydroxide (1.1 g, 0.0275 mol), water (10 ml) and rectiÞ ed spirit (6 ml). To this mixture 4-methoxybenzaldehyde (5b) (2.9 g, 0.0215 mol) was added drop wise maintaining the temperature at <200. After the addition was over, the reaction mixture was stirred vigorously until the reaction mixture became thick. It was cooled overnight in ice chest. The solid obtained was Þ ltered and washed with cold water and rectiÞ ed spirit. The crude chalcone, 3-(4-methoxyphenyl)-1-phenylprop- 2-en-1-one (6b) was dried and recrystallised from rectified spirit. The compounds 6a, 6c-o were synthesized by the same method described above using 4-chloroacetophenone, 4-hydroxyacetophenone and different aromatic aldehydes.

To a solution of 3-(4-methoxyphenyl)-1-phenylprop- 2-en-1-one (6b) (1.38 g, 0.005 mol) in dioxane (25 ml), acetic acid (0.5 ml) was added and the mixture was kept for stirring for 30 minutes. To this mixture naphtho-[2,1-b]furan-2-carbohydrazide (3) (1.01g, 0.005 mol) was added and refluxed for 24 h. After completion of the reaction, the reaction mixture was poured to ice cold water, solid separated was Þ ltered and dried. The crude product was recrystallised from ethanol. The compounds 7a, 7c-o were synthesized similarly from 6a, 6c-o. The characterization data of the synthesized compounds are reported in Table 1. The structures of newly synthesized compounds were elucidated by IR, NMR spectral studies, which are reported in Table 2.

Table 1:Characterization Data of the Compounds 7a-O.

Table 2: Ir And Nmr Spectral Data of 2-(1-Naphtho[2,1-B]Furan-2-Yl-Carbonyl)-3,5-Disubstituted-2,3-Dihydro-1h-Pyrazoles.

Antimicrobial activity

The in vitro antimicrobial activity was carried out against 24 h old cultures of two bacteria and two fungi by cup-plate method [18]. The compounds (7a-o) have been tested for their antibacterial activity against Pseudomonas aeruginosa and Staphylococcus aureus and antifungal activity against Aspergillus niger and Curvularia lunata. Chloramphenicol and ß uconazole were used as standards for antibacterial and antifungal activity respectively. The compounds were tested at a concentration in of 0.001 mol/ml in DMF against all the organisms. The zone of inhibition was compared with the standard drug after 24 h of incubation at 250 for antibacterial activity and 48 h at 300 for antifungal activity. The results are reported in Table 3.

Table 3: Regulatory Requirements Under European Committee For Normalization [5].

Antiinfl ammatory activity

The antiinflammatory activity was evaluated by a rat paw edema method, which is based on plethysmographic measurement of carrageenaninduced acute rat paw edema [19-20]. For this study, wistar rats of either sex, weighing between 100-200 g, were used and were divided into 7 groups, of 4 animals each. The group I served as control, the group II received ibuprofen and served as standard, and the groups III–VII received orally the test compounds. These drugs were administered 1 h before the injection of carrageenan. After 1 h all the animals were injected subcutaneously with a suspension of carrageenan in Tween-80 (0.1%, 0.05 ml) solution to the left hind paw in the subplantar region and the paw volume was measured immediately. After 3 h the paw volume was measured in control, in standard and in test groups. Percent inhibition of paw volume was calculated using the formula, % inhibition= (1-Vt/Vc)×100, where, Vt is the mean increase in the paw volume in test animals group and Vc is the mean increase in the paw volume in control group. The results are reported in Table 4.

Table 4: Antiinflammatory Activity of Compounds 7a-E.

Analgesic activity

Analgesic activity was determined by the method based on acetic acid- induced writhing in mice [21-22]. For this experiment, colony bred swiss mice of either sex weighing 25-35 g mice were divided into control, standard and different test groups containing 6 animals each. The results are reported in Table 5. Percent inhibition of writhing was calculated using the formula, % Inhibition= (1–Nt/Nc)×100, where, Nt is the mean number of writhing in test animals and Nc represented mean number of writhing in control.

Table 5: Classification For Medical Devices By Australian Register For Therapeutic Goods 7.

Anthelmintic activity

Anthelmintic activity was evaluated using Pheritima posthuma (class-Annelida and order-Oligichaeta). The technique adopted was that described by Giand et al. [23] with slight modification [24]. The worms with normal motility were selected for the experiment and albendazole is used as standard for comparison of the activity. The results are tabulated in Table 6.

Table 6: Anthelmintic Activity of Compounds 7a-O.

Diuretic activity

The diuretic activity was evaluated on wistar rats using the method reported by Lipschitz [25]. Rats of either sex, weighing between 100-200 g were divided into 7 groups, each containing 6 animals. Group I served as control, group II served as standard. The groups III-VII received orally the test compounds at the dose of 30 mg/kg body weight in Tween-80 (0.1%, 5 ml). Each group of animals was kept in different metabolic cages provided with a wire mesh at the bottom and a funnel to collect urine. Urine excreted was collected after 5 h and the values are tabulated in Table 7.

Table 7: Results of Diuretic Activity of Compounds 7a-E.

Antipyretic activity

The antipyretic activity was carried out on wistar rats as described by the method based on yeast-induced hyperpyrexia method [26]. The rats weighing 150-170 g were selected and divided into 6 groups each having 6 animals. The rectal temperature and its hourly variation were recorded at the beginning of the experiment using a digital Telethermometer. The rats showing rise in rectal temperature of 0.50 or more were distributed in to different group of 6 each and test drugs, Group I received tween–80 as control and group-II received paracetamol as standard drug and groups III-VI received test compounds. The decrease in rectal temperature was noted using telethermometer at 1 h intervals up to 3 h. All values are expressed as mean±SEM. The results are reported in Table 8.

Table 8: Showing age and sex distribution of the patient in peritoneal fluid.

Results and Discussion

The required starting material to accomplish the synthesis of title compounds, ethyl naphtho[2,1-b] furan-2-carboxylate (2) was obtained by the reaction of 2-hydroxy-1-naphthaldehyde (1) with ethyl chloroacetate in presence of anhydrous potassium carbonate and in dry DMF at reflux temperature. Both condensation as well as cyclisation occurred in single step and produced ethyl naphtho-[2,1-b]furan- 2-carboxylate (2) in good yield. The reaction of ethyl naphtho-[2,1-b]furan-2-carboxylate (2) with hydrazine hydrate in presence of acid catalyst in ethanol produced naphtho-[2,1-b]furan-2-carbohydrazide (3). The synthetic route is shown in Scheme 1.

The chalcones (6a-o) were synthesized by Claisen condensation between substituted acetophenones (4a-c) and different aromatic aldehydes [27] (5a-e). The selection of substituted acetophenones and substituted aromatic aldehydes was based on presence of electron withdrawing and electron releasing groups which would assist in later studies, on structure activity relationship. The synthetic route shown in Scheme 2.

The reaction of naphtho[2,1-b]furan-2-carbohydrazide (3) with chalcones 6a-o to obtain the title compounds (7a-o) was attempted by employing various reagents and reaction conditions. However, the desired condensation was successful only when the reaction was carried out by using acetic acid as catalyst and dioxane as a solvent at reß ux temperature. The target compounds 1-(naphtho[2,1-b]furan-2-ylcarbonyl)-3,5- disubstituted-2,3dihydro-1H-pyrazoles (7a-o) were obtained in good yield. The synthetic route is shown in Scheme 3.

The compounds containing naphthofuran were known to exhibit a wide spectrum of biological and pharmacological activities [28-30]. Hence, it was intrigued to evaluate newly synthesized compounds for antimicrobial, antiinflammatory, analgesic, anthelmintic, diuretic and antipyretic activities by adopting literature procedure.

The newly synthesized compounds were evaluated for antimicrobial activity by cup-plate method. Antibacterial activity was evaluated against Pseudomonas aerugenosa and Staphylococcus aureus using chloramphenicol as standard drug, The compounds 7i, 7k, 7l, 7m and 7o exhibited activity against P. aerugenosa, while compound 7n showed activity against S. aureus. For antifungal activity Aspergillus niger and Curvularia lunata were used as test organisms and ß uconazole as standard drug. The compounds 7a-o shows lesser activity than the standard drugs.

Among the compounds tested for antiinflammatory activity, the compounds 7a-e shows lesser activity than the standard drugs. The results of anthelmintic activity indicate that most of the compounds were found to be less active than the standard drugs. The compounds 7a-e were found to display lesser activity when compared to standard drug. The results of antipyretic activity indicated that compound 7e exhibited equal antipyretic activity of reducing the temperature to the extent of 0.4°. Rest of the compounds was less active than the standard drug. From these results it is possible to conclude that most of the synthesized compounds were pharmacologically active. However, no conclusion could be drawn on the effect of electron donating or electron withdrawing groups on pharmacological activities.

Acknowledgements

The authors thank the Chairman, Department of Chemistry, Kuvempu University and the Principal, SCS College of Pharmacy, Harapanahalli for providing laboratory facilities, the Convener, Sophisticated Instruments Facility, IISc, Bangalore for providing spectral data and to UGC for awarding Senior Research Fellowship (to MNK).

References

1. Park HJ, Lee JC, Kim YJ, Lee KI. Unexpected behavior of 5-phenoxy pyrazoles derivatives. Bull Korean Chem Soc 2005;26:4.
2. Tabarelli Z, Rubin MA, Berlese DB, Sauzem PD, Missio TP, Teixeira MV, et al. Antinoceptive effect of novel pyrazolines in mice. Braz J Med Biol Res 2004;37:1531.
3. Kidwai M, Goel Y, Kumar R. Microwave assisted synthesis and antifungal activity of 1,2,4-triazine, 1,2,4-triazole, tetrazole and pyrazoles derivatives. Indian J Chem 1998;37B:174.
4. Greenhill JV. Pyrazoles with fused six-membered heterocyclic ring. In: Katritzky AR, Rees CW, editors. Comprehensive heterocyclic chemistry. Vol. 5. Oxford: Pergamon Press; 1984. p. 302.
5. Verma RK, Nayal SS. Study of insecticidal activity of some pyrazoles derivatives against American cockroaches. Indian J Chem Tech 2003;10:347.
6. Bruno O, Ranise A, Bondavalli F, Schenone P, D?Amico M, Filippelli A, et al. 3,5 diphenyl-1H-pyrazole derivatives XI. N-aryl-5(3)-phenyl- 4-(3,5-diphenyl-1-pyrazolyl)-3(5) pyrazole amines, 5-substituted 4,5-dihydro-3-phenyl-4-(3,5-diphenyl-1-pyrazolyl)-1H pyrazoles and 2,6-disubstituted-1,6-dihydro-4-phenyl-5-(3,5-diphenyl-1-pyrazolyl)
7. pyrimidines with antipyretic, antiinß ammatory and other activities. Il Farmaco 1993;48:949.
8. Lubs HA. In the chemistry of synthetic dyes and pigments. Washington: American Chem Soc; 1970.
9. Vicentini CB, Romagnoli C, Andreotti E, Mares D. Synthetic pyrazole derivatives as growth inhibitors of some phytopathogenic fungi. J Agric Food Chem 2007;55:10331.
10. Manna F, Chimenti F, Fioravanti R, Bolasco A, Secci D, Chimenti P, et al. Synthesis of some pyrazoles derivatives and preliminary investigation of their afÞ nity binding to p-gylcoprotein. Bioorg Med Chem Lett 2005;15:4632.
11. Harinadhababu V, Manna SK, Srinivasan KK, Bhat VG. Synthesis and biological evaluation of 1,3,5-trisubstituted pyrazolines bearing benzofurans. Indian J Heterocycl Chem 2004;13:253.
12. Ravindra KC, Vagdevi HM, Vaidya VP. Synthesis and antimicrobial activity of novel naphtho[2,1-b]furo-5H-[3,2-d][1,3,4]thiadiazolo[3,2-a] pyrimidin-5-one. ARKIVOC 2008;11:1.
13. Mahadevan KM, Vaidya VP. Synthesis and pharmacological evaluation of some potent naphtho[2,1-b]furo-pyrazolyl, oxadiazolyl and coumaryl derivatives. Indian J Pharm Sci 2003;65:128.
14. Kumaraswamy MN, Prathima Mathias DA, Chandrashekhar C, Vaidya VP. Synthesis and pharmacological evaluation of 2-mercapto-4- substituted-naphtho[2,1-b]furo[3,2-d] pyrimidines. Indian J Pharm Sci 2006;68:731.
15. Kumaraswamy MN, Vaidya VP. Novel method for the synthesis of symmetrical and asymmetrical azines involving naphtho[2,1-b]furan and their antimicrobial activity. Indian J Heterocycl Chem 2005;14:193.
16. Mahadevan KM, Vaidya VP, Vagdevi HM. Synthesis of novel naphtho- [2,1 b]furopyrimidine derivatives. Indian J Chem 2003;42B:1931.
17. Nagaraj GK, Kumaraswamy MN, Vaidya VP, Mahadevan KM. Microwave assisted synthesis of naphtho[2,1-b]furan,1,3,4-benzotriazepines. A potent antimicrobial agent. ARKIVOC 2006;10:211.
18. Vagdevi HM, Vaidya VP. Studies in naphthofurans: Part III. Synthesis of 2-substituted naphtho[2,1-b]furans, 2-(2?-aryl-3?-acetyl-1?,3?,4?- oxadiazolyl)aminonaphtho[2,1-b]furans and their biological activities. Indian J Heterocycl Chem 2001;10:253.
19. Seely HW, Van Demark PJ. Microbes in action: A laboratory manual of Microbiology, Mumbai: DB Taraporewala Sons and Co; 1975. p. 55.
20. Mukhanova TI, Lykova OA, Alekseeva LM, Granik VG. New approach to synthesis of derivatives of 2-(5-hydroxybenzofuryl-3)naphthofurans. Chem Heterocycl Compd 1998;34:651.
21. Lambert RJ, Pearson J. Susceptibility testing: Accurate and reproducible minimum inhibitory concentration (MIC) and noninhibitoryconcentration (NIC) values. J Appl Microbiol 2000;88:784.
22. Koster R, Anderson M, Olbur EJ. Acetic-acid for analgesic screening. Fed Proc 1959;18:412.
23. Turner RA. Analgesics in: Screning methods in pharmacology. New York: Academic Press; 1965.
24. Aswar M, Aswar U, Watkar B, Vyas M, Wagh A, Gujar KN. Anthelmintic activity of Ficus benghalensis. Int J Green Pharm 2008;2:170.
25. Kalluraya B, Sreenivasa S. Synthesis and pharmacological properties of some quinoline derivatives. Il Farmaco 1998;53:399.
26. Lipschitz WL, Hadidian Z, Kerpscar A. Bioassy of diuretics. J Pharmacol Exp Ther 1943;79:97-110.
27. Hukkeri VI, Patil BS, Savadi RV, Nagarathna CV. Analgesic, antipyretic and diuretic activities of Basella rubralinn. Indian Drugs 2004;41:536.
28. Furniss BS, Hannaford AJ, Smith PW, Tatchell AR. Vogel?s textbook of practical organic chemistry, 5th ed. ELBS Publication; 1989; p. 1034.
29. Ramesh D, Chandrashekhara C, Vaidya VP, Synthesis of novel naphtho[2,1-b]fur[3,2-b]pyridine derivatives as a potential antimicrobial agents. Indian J Chem 2008;47B;753.
30. Rajashekhara H, Ramesh D, Chandrashekhara C, Mahadevan KM, Vaidya VP. Synthesis of 2-(3-nitronaphtho[2,1-b]furan-2-yl)-5-substituted-1,3,4-oxadiazoles and their biological activities. Indian J Heterocycl Chem 2007;16;353.
31. Chandrashekhara C, Kumaraswamy MN, Basavaraj KM, Vaidya VP. Synthesis, antimicrobial and anthelmintic activities of 2,9-disubstituted [2,1-b]furans. Indian J Heterocycl Chem. 2007;16;341.